2020;8:789 99. 26. Velazquez EJ, Morrow DA, DeVore AD, et al. Rationale and design of the comparIson of sacubitril/ valsartan versus enalapril on effect on NT-Pro-BNP in patients stabilized from an acute heart failure episode (PIONEER-HF) trial. Am Heart J. 2018;198:145 51. 27. McAlister F, Wiebe N, Ezekowitz J, et al. Meta- analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150:784 94. 28. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a rand- omised placebo-controlled study. Lancet. 2010;376: 875 85. 29. Swedberg K, Komajda M, Bohm M, et al. Effects on outcomes of heart rate reduction by ivabradine in pa- tients with congestive heart failure: is there an in u- ence of beta-blocker dose? Findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012;59: 1938 45. 30. Bohm M, Borer J, Ford I, et al. Heart rate at baseline in uences the effect of ivabradine on cardio- vascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102:11 22. 31. Das SR, Everett BM, Birtcher KK, et al. 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiol- ogy Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76:1117 45. 32. Zelniker TA, Braunwald E. Mechanisms of car- diorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:422 34. 33. Nassif ME, Windsor SL, Tang F, et al. Dapagli ozin effects of biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF Trial. Circulation. 2019;140: 1463 76. 34. 